Who are Recombinant Human Interleukin-11's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, Late receiving G-CSF group, Early receiving G-CSF group, vemurafenib + HD IL-2, Gamma Interferon 1b, vunakizumab and recaticimab..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-human-interleukin-11.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Recombinant Human Interleukin-11 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant Human Interleukin-11 (Recombinant Human Interleukin-11) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine; thrombopoietic agent. Area: Oncology; Hematology.

phase 3 Cytokine; thrombopoietic agent IL-11 receptor (IL-11R) Oncology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant Human Interleukin-11 (Recombinant Human Interleukin-11) — Zhejiang Cancer Hospital. Recombinant human interleukin-11 (rhIL-11) stimulates megakaryocyte maturation and platelet production to prevent or treat chemotherapy-induced thrombocytopenia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant Human Interleukin-11 TARGET	Recombinant Human Interleukin-11	Zhejiang Cancer Hospital	phase 3	Cytokine; thrombopoietic agent	IL-11 receptor (IL-11R)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
Late receiving G-CSF group	Late receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
Early receiving G-CSF group	Early receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
vemurafenib + HD IL-2	vemurafenib + HD IL-2	Clinigen, Inc.	marketed	BRAF inhibitor + cytokine immunotherapy	BRAF V600E kinase; IL-2 receptor
Gamma Interferon 1b	Gamma Interferon 1b	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Cytokine; Interferon	Interferon-gamma receptor (IFNGR)
vunakizumab and recaticimab.	vunakizumab and recaticimab.	Xiangya Hospital of Central South University	marketed	Monoclonal antibody (anti-cytokine)	IL-12/IL-23 p40 subunit (vunakizumab); TNF-α (recaticimab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine; thrombopoietic agent class)

Zhejiang Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Human Interleukin-11 — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-interleukin-11. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing